July 29, 2026- BD and EMS, one of Brazil’s leading pharmaceutical companies, announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients’ ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes. EMS’s semaglutide utilizes BD’s established injection pen platform, which features an intuitive design built for ease of use. The BD Vystra™ Injection Pen platform reflects BD’s deep expertise in drug delivery systems design and manufacturing, supporting scalable solutions that can help meet rising demand for injectable therapies.